Denái R. Milton, M.S.
Senior Statistical Analyst
- Master of Science, Biostatistics, University of North Carolina – School of Public Health, Chapel Hill, NC
- Bachelor of Engineering, Biomedical Engineering and Mathematics, Vanderbilt University, Nashville, TN
- Health Outcomes
- Behavioral Statistics
Dennehy EB, Kahle-Wrobleski K, Sarsour K, Milton DR. Derivation of a brief measure of agitation and
aggression in Alzheimer’s disease. International Journal of Geriatric Psychiatry 2012; DOI:
Sarsour K, Johnston JA, Milton DR, Duhig A, Melfi C, Moss HB. Factors predicting change in frequency of heavy drinking among alcohol-dependent participants in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Alcohol and Alcoholism 2012; 47(4): 443-50.
Cuyún Carter GB, Milton DR, Ascher-Svanum, H, Faries, DE. Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry 2011; 11: 143.
Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. Child and Adolescent Psychiatry and Mental Health 2008; 2: 25.
Moretto TJ, Milton DR, Ridge TD, MacConell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2008; 30(8): 1448-60.
Biederman J, Spencer T, Newcorn J, Gao H, Milton D, Feldman PD, Witte MM. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology 2007; 190: 31-41.
Spencer TJ, Sallee FR, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Gilbert DL, Geller DA, Linder SL, Lewis DW, Winner PK, Kurland RM, Mintz M, Milton DR, Feldman PD, Kelsey DK. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal for Attention Disorder 2008; 11(4): 470-81.
Zinman B, Hoogwerf BJ, García SD, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Annals of Internal Medicine 2007; 146: 477-85.
Adler LA, Spencer TJ, Milton DR, Moore RJ, Jones D, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry 2005; 66: 294-9.
Wernicke JF, Faries D, Milton D, Weyrauch K. Detecting treatment emergent adverse events in clinical trials: A comparison of spontaneously reported and solicited collection methods. Drug Safety 2005; 28(11): 1057-63.
Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65: 1941-9.
Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo controlled assessment. Journal of Clinical Psychopharmacology 2004; 24: 1-6.
Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tohen M. Placebo-controlled trials do not find association with exacerbation of bipolar mania. Journal of Affective Disorders 2003; 73: 147-53.
Michelson D, Adler L, Spencer T, Reimherr F, West S, Allen A, Kelsey D, Dietrich A, Milton D. Atomoxetine in adults with attention-deficit/hyperactivity disorder: Two randomized, placebo-controlled studies. Biological Psychiatry 2003; 53: 112-20.
Tohen M, Baker RW, Altshuler L, Zarate CA, Ketter TA, Milton DR, Risser R, Gilmore JA, Brier A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. The American Journal of Psychiatry 2002; 159: 1011-7.
Baker RW, Goldberg JF, Tohen M, Milton DR, Stauffer VL, Schuh LM. The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. Bipolar Disorders 2002; 4: 43-9.
Kratochvil C, Heiligenstein J, Dittmann R, Spencer T, Biederman J, Wernicke J, Newcorn J, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of American Academy of Child and Adolescent Psychiatry 2002; 41(7): 776-84.
Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. The American Journal of Psychiatry 2002; 159: 1011-7.
Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. Journal of Clinical Psychiatry 2001; 62[suppl 2]: 17-21.